SH3BP2

SH3BP2
Available structures PDB Ortholog search: PDBe RCSB List of PDB id codes 2CR4, 3TWR
Identifiers
Aliases	SH3BP2, 3BP-2, 3BP2, CRBM, CRPM, RES4-23, SH3 domain binding protein 2
External IDs	OMIM: 602104; MGI: 1346349; HomoloGene: 2276; GeneCards: SH3BP2; OMA:SH3BP2 - orthologs
Gene location (Human) Chr. Chromosome 4 (human)[1] Band 4p16.3 Start 2,793,071 bp[1] End 2,841,098 bp[1]
Gene location (Mouse) Chr. Chromosome 5 (mouse)[2] Band 5|5 B2 Start 34,683,182 bp[2] End 34,720,985 bp[2]
RNA expression pattern Bgee Human Mouse (ortholog) Top expressed in granulocyte sural nerve monocyte spleen skin of abdomen blood skin of leg upper lobe of left lung ganglionic eminence right lung Top expressed in granulocyte secondary oocyte zygote primary oocyte stroma of bone marrow spleen ganglionic eminence ventricular zone genital tubercle blood More reference expression data BioGPS n/a
Orthologs Species Human Mouse Entrez 6452 24055 Ensembl ENSG00000087266 ENSMUSG00000054520 UniProt P78314 Q06649 RefSeq (mRNA) NM_001122681 NM_001145855 NM_001145856 NM_003023 NM_001136088 NM_001145858 NM_001145859 NM_011893 RefSeq (protein) NP_001116153 NP_001139327 NP_001139328 NP_003014 n/a Location (UCSC) Chr 4: 2.79 – 2.84 Mb Chr 5: 34.68 – 34.72 Mb PubMed search [3] [4]
Wikidata
View/Edit Human View/Edit Mouse

SH3 domain-binding protein 2 is a protein that in humans in encoded by the SH3BP2 gene located on Chromosome 4.

Tissue distribution

This protein is widely expressed in hematopoietic cells, including: macrophages, B and T lymphocytes, and osteoclast progenitor cells.

Structure

SH3 domain-binding protein 2 (SH3BP2) is a modular adaptor protein with a distinctive domain architecture that enables its functional roles in signal transduction and immune regulation. The structure of SH3BP2 includes an N-terminal pleckstrin homology (PH) domain that binds membrane phosphatidylinositol lipids and facilitates associations with G proteins and protein kinase C. This is followed by a central proline-rich region, which is responsible for interacting directly with SH3 domains of other proteins, making SH3BP2 a key scaffold in assembling signaling complexes. Finally, the C-terminal Src homology 2 (SH2) domain enables recognition and binding of phosphotyrosine motifs, further expanding its repertoire of signaling partners. SH3BP2 undergoes multiple phosphorylation events on tyrosine and serine residues, which modulate its function and binding interactions, and is subject to post-translational modifications such as ADP-ribosylation and ubiquitination.^[5][6]

Function

It functions as an adaptor protein involved in signaling pathways, in concert with SRC kinases, SYK, and PLCγ, affecting immune cell activation, inflammatory signaling, and bone metabolism-- it is also associated with cherubism. It binds to phosphatidylinositol, linking the hemopoietic tyrosine kinase fes to the cytoplasmic membrane in a phosphorylation-dependent mechanism.

Clinical significance

Bone reabsorption

A gain-of-function mutation in the protein's exon 9 region leads to several common mutations that affect its proline-rich domain, resulting in its hyperactivation. This upregulation of SH3BP2 increases osteoclast formation and activity, causing bone reabsorption and cyst-like lesions in a TNF-α-dependent mechanism.^[7]

Mutated SH3BP2 can lead to upregulation of pro-inflammatory cytokines, including Tumor Necrosis Factor-alpha (TNF-α), interleukin 1-beta (IL-1β), and RANKL, creating a positive feedback loop furthering osteoclast activation.^[8]

Cherubism

SH3BP2 is the key gene implicated in cherubism, a rare autosomal dominant disorder marked by painless, symmetric swelling of the jaw due to excessive bone resorption and replacement with fibro-osseous tissue. Gain-of-function mutations in SH3BP2 enhance osteoclast formation and activity, particularly in response to signaling molecules like RANKL and TNF-α, resulting in the formation of characteristic jawbone lesions containing abundant multinucleated giant cells. Experimental models and patient analyses have revealed elevated inflammatory cytokines (including TNF-α and IL-1β) in cherubism, highlighting SH3BP2’s central role in modulating both osteoclastogenesis and sterile inflammatory bone loss.^[7][8]

Gastrointestinal stromal tumors

SH3BP2 is a key regulator in the growth and survival of gastrointestinal stromal tumors. It supports the expression of two transcriptional factors, ETV1 and MITF, and receptor kinases, KIT and PDGFRA.

There are certain therapies for GISTs that involve silencing SH3BP2 to reduce the expression of the receptor kinases KIT and PDGFRA, which are commonly mutated and drive GISTs development.^[9] The silencing of the adaptor protein, SH3BP2, also indirectly downregulates ETV1 and MITF, through miRNA-mediated post-transcriptional repression.^[10]

See also

• SH3 domain

References

1. GRCh38: Ensembl release 89: ENSG00000087266 – Ensembl, May 2017
2. GRCm38: Ensembl release 89: ENSMUSG00000054520 – Ensembl, May 2017
3. "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
4. "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
5. McMahon MS, Ueki Y (February 2009). "SH3BP2 is a critical regulator of macrophage and osteoclast response to M-CSF and RANKL stimulation". HSS Journal : the Musculoskeletal Journal of Hospital for Special Surgery. 5 (1): 49–50. doi:10.1007/s11420-008-9091-6. PMC 2642551. PMID 18953613.
6. Srivastava T, Sharma M (2025). "Emerging Role of SH3BP2 as Regulator of Immune and Nonimmune Cells in Nephrotic Syndrome". Glomerular Diseases. 5 (1): 1–12. doi:10.1159/000542703. PMC 11842026. PMID 39991193.
7. Mukai T, Ishida S, Ishikawa R, Yoshitaka T, Kittaka M, Gallant R, et al. (December 2014). "SH3BP2 cherubism mutation potentiates TNF-α-induced osteoclastogenesis via NFATc1 and TNF-α-mediated inflammatory bone loss". Journal of Bone and Mineral Research. 29 (12): 2618–2635. doi:10.1002/jbmr.2295. PMC 4262741. PMID 24916406.
8. Reichenberger EJ, Levine MA, Olsen BR, Papadaki ME, Lietman SA (May 2012). "The role of SH3BP2 in the pathophysiology of cherubism". Orphanet Journal of Rare Diseases. 7 Suppl 1 (Suppl 1): S5. doi:10.1186/1750-1172-7-S1-S5. PMC 3359958. PMID 22640988.
9. Serrano-Candelas E, Ainsua-Enrich E, Navinés-Ferrer A, Rodrigues P, García-Valverde A, Bazzocco S, et al. (August 2018). "Silencing of adaptor protein SH3BP2 reduces KIT/PDGFRA receptors expression and impairs gastrointestinal stromal tumors growth". Molecular Oncology. 12 (8): 1383–1397. doi:10.1002/1878-0261.12332. PMC 6068349. PMID 29885053.
10. Proaño-Pérez E, Serrano-Candelas E, Mancia C, Navinés-Ferrer A, Guerrero M, Martin M (December 2022). "SH3BP2 Silencing Increases miRNAs Targeting ETV1 and Microphthalmia-Associated Transcription Factor, Decreasing the Proliferation of Gastrointestinal Stromal Tumors". Cancers. 14 (24): 6198. doi:10.3390/cancers14246198. PMC 9777313. PMID 36551682.

External links

• GeneReviews/NCBI/NIH/UW entry on Cherubism
• SH3BP2+protein,+human at the U.S. National Library of Medicine Medical Subject Headings (MeSH)
• Genetics Home Reference on SH3BP2